Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021 Apr;126(4):385-93. doi: 10.1016/j.anai.2020.12.015
Molfino NA, Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Real world evidence in asthma: pulmonary function and asthma control in respiratory specialty clinics in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Molfino NA, Averell CM, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Slade DJ. Patients with uncontrolled asthma eligible for a biologic. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 20, 2020. Philadelphia, PA.
Averell CM, Hahn B, Zografos L, Gilsenan A, Richardson D, McSorley D, Molfino NA, Slade DJ. Assessment of asthma control in respiratory specialist offices in the US. Poster presented at the 2020 American Thoracic Society (ATS) International Conference; May 17, 2020. Philadelphia, PA.
Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9
Davis K, Asiimwe A, Zografos L, McSorley D. Evaluation of risk minimisation activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):309-10.